Knoa Pharma's new CEO, Michael Goettler, will lead a company that was created through Purdue Pharma's bankruptcy process.
Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug ...
Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果